PipelineReview.com2h
PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy
PARIS, France I January 14, 2025 I PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with ...
PipelineReview.com2h
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
ROCKVILLE, MD, USA I January 14, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership ...
PipelineReview.com2h
Ex-Deep Genomics, Moderna Execs Get Backing Led by Gradient to Develop Next-Generation mRNA Therapeutics with AI
SAN FRANCISCO, CA, USA I January 13, 2025 I Kerna Laboratories Inc, a San Francisco-based AI biotech startup, emerged from stealth with the launch of an AI ...
PipelineReview.com2h
Pheno Therapeutics Granted Clinical Trial Authorisation for Lead Multiple Sclerosis Therapeutic Candidate PTD802
EDINBURGH, UK I January 14, 2025 I Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule ...
PipelineReview.com19h
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SHANGHAI, China and NORTH CHICAGO, IL, USA I January 13, 2025 I Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc.
PipelineReview.com19h
CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
SHANGHAI, China I January 13, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...
PipelineReview.com19h
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
NORTH CHICAGO, IL and ROCKVILLE, MD, USA I January 13, 2025 I AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ...
PipelineReview.com19h
Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor ...
PipelineReview.com1d
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
TEL AVIV, Israel I January 13, 2025 I Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) ...
PipelineReview.com1d
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
NEW HAVEN, CT, USA and UTRECHT, The Netherlands and CAMBRIDGE, MA, US AI January 12, 2025 I Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), ...
PipelineReview.com1d
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
MELBOURNE, Australia and INDIANAPOLIS, IN, USA I January 12, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today ...
PipelineReview.com1d
GSK Enters Agreement to Acquire IDRx, Inc.
PLYMOUTH, MA, USA I January 13, 2025 I GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK ...